Fanciulli Giuseppe, Modica Roberta, La Salvia Anna, Campolo Federica, Florio Tullio, Mikovic Nevena, Plebani Alice, Di Vito Valentina, Colao Annamaria, Faggiano Antongiulio
Neuroendocrine Tumour Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari-Endocrine Unit, AOU Sassari, 07100 Sassari, Italy.
Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, 80131 Naples, Italy.
Cancers (Basel). 2022 Aug 18;14(16):3991. doi: 10.3390/cancers14163991.
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with variable clinical presentation and prognosis. Surgery, when feasible, is the most effective and often curative treatment. However, NENs are frequently locally advanced or already metastatic at diagnosis. Consequently, additional local or systemic therapeutic approaches are required. Immunotherapy, based on chimeric antigen receptor T cells (CAR-T), is showing impressive results in several cancer treatments. The aim of this narrative review is to analyze the available data about the use of CAR-T in NENs, including studies in both preclinical and clinical settings. We performed an extensive search for relevant data sources, comprising full-published articles, abstracts from international meetings, and worldwide registered clinical trials. Preclinical studies performed on both cell lines and animal models indicate a significant therapeutic effect of CAR-T cells in NENs. Ongoing and future clinical trials will clarify the possible role of these drugs in patients with highly aggressive NENs.
神经内分泌肿瘤（NENs）是一组异质性肿瘤，临床表现和预后各不相同。手术在可行时是最有效且通常能治愈的治疗方法。然而，NENs在诊断时常常已局部进展或发生转移。因此，需要额外的局部或全身治疗方法。基于嵌合抗原受体T细胞（CAR-T）的免疫疗法在几种癌症治疗中显示出令人瞩目的效果。本叙述性综述的目的是分析关于CAR-T在NENs中应用的现有数据，包括临床前和临床研究。我们广泛搜索了相关数据源，包括已全文发表的文章、国际会议摘要以及全球注册的临床试验。在细胞系和动物模型上进行的临床前研究表明，CAR-T细胞在NENs中具有显著的治疗效果。正在进行的和未来的临床试验将阐明这些药物在高度侵袭性NENs患者中的可能作用。
